Commons Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Commons Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.6K	Sell	10,620 -1,870	-15%	-$7.23K	0.03%	82
2025 Q4	$51.1K	Sell	12,490 -106,818	-90%	-$529K	0.03%	109
2025 Q3	$582K	Buy	119,308 +1,786	+2%	+$9.38K	0.38%	54
2025 Q2	$595K	Buy	117,522 +8,426	+8%	+$41.4K	0.45%	48
2025 Q1	$577K	Buy	109,096 +576	+0.5%	+$4.2K	0.53%	42
2024 Q4	$734K	Sell	108,520 -7,439	-6%	-$50K	0.66%	35
2024 Q3	$764K	Buy	115,959 +4,852	+4%	+$34.8K	0.84%	26
2024 Q2	$833K	Buy	+111,107	New	+$969K	1%	23

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commons Capital's RXRX Position: Q1 2026 in Review

Commons Capital reduced its Recursion Pharmaceuticals (RXRX) stake by 15% in Q1 2026, selling an estimated $7.23K and leaving 10,620 shares worth $32.6K. The position accounts for 0.03% of the portfolio, ranked #82.

Commons Capital first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $833K in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Commons Capital held 10,620 shares of Recursion Pharmaceuticals worth $32.6K as of Q1 2026.
Commons Capital sold 1,870 Recursion Pharmaceuticals shares in Q1 2026, an estimated $7.23K.
Recursion Pharmaceuticals made up 0.03% of Commons Capital's portfolio in Q1 2026, its #82 holding.
Commons Capital first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Commons Capital's Recursion Pharmaceuticals position peaked at $833K in Q2 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Commons Capital's 13F filing for Q1 2026, filed 30 Apr 2026.